Ciampelli C, Galleri G, Galioto M, Mereu P, Pirastru M, Bernardoni R
Int J Mol Sci. 2025; 26(5).
PMID: 40076730
PMC: 11900240.
DOI: 10.3390/ijms26052093.
Zhu H, Sydor A, Yan B, Li R, Boniecki M, Lyons C
Nat Commun. 2025; 16(1):2329.
PMID: 40057496
PMC: 11890592.
DOI: 10.1038/s41467-025-57453-x.
Li X, Zhu H, Huang B, Li X, Kim H, Tan H
Nat Commun. 2024; 15(1):8434.
PMID: 39343966
PMC: 11439917.
DOI: 10.1038/s41467-024-52723-6.
Ferrari V, Tedesco B, Cozzi M, Chierichetti M, Casarotto E, Pramaggiore P
Cell Mol Biol Lett. 2024; 29(1):116.
PMID: 39237893
PMC: 11378602.
DOI: 10.1186/s11658-024-00633-2.
Tanaka M, Vecsei L
J Neural Transm (Vienna). 2024; 131(12):1367-1387.
PMID: 39110245
PMC: 11608389.
DOI: 10.1007/s00702-024-02812-z.
Mechanisms of lysosomal tubulation and sorting driven by LRRK2.
Bonet-Ponce L, Kluss J, Cookson M
Biochem Soc Trans. 2024; 52(4):1909-1919.
PMID: 39083004
PMC: 11668303.
DOI: 10.1042/BST20240087.
RAB12-LRRK2 Complex Suppresses Primary Ciliogenesis and Regulates Centrosome Homeostasis in Astrocytes.
Li X, Zhu H, Huang B, Li X, Kim H, Tan H
bioRxiv. 2024; .
PMID: 39071328
PMC: 11275936.
DOI: 10.1101/2024.07.17.603999.
Evaluation of Neuroinflammatory Contribution to Neurodegeneration in LRRK2 Models.
Nguyen H, Galleri G, Rassu A, Ciampelli C, Bernardoni R, Galioto M
Biomedicines. 2024; 12(7).
PMID: 39062128
PMC: 11274873.
DOI: 10.3390/biomedicines12071555.
Opposing actions of JIP4 and RILPL1 provide antagonistic motor force to dynamically regulate membrane reformation during lysosomal tubulation/sorting driven by LRRK2.
Bonet-Ponce L, Tegicho T, Beilina A, Kluss J, Li Y, Cookson M
bioRxiv. 2024; .
PMID: 38903076
PMC: 11188082.
DOI: 10.1101/2024.04.02.587808.
The Impact of LRRK2 G2019S on Parkinson's Disease: Clinical Phenotype and Treatment in Tunisian Patients.
Barreh G, Sghaier I, Abida Y, Gharbi A, Nasri A, Mrabet S
J Mov Disord. 2024; 17(3):294-303.
PMID: 38649328
PMC: 11300391.
DOI: 10.14802/jmd.23276.
iSCORE-PD: an isogenic stem cell collection to research Parkinson's Disease.
Busquets O, Li H, Syed K, Jerez P, Dunnack J, Lo Bu R
bioRxiv. 2024; .
PMID: 38405931
PMC: 10888955.
DOI: 10.1101/2024.02.12.579917.
Blocking IL-6 signaling prevents astrocyte-induced neurodegeneration in an iPSC-based model of Parkinson's disease.
Pons-Espinal M, Blasco-Agell L, Fernandez-Carasa I, Andres-Benito P, di Domenico A, Richaud-Patin Y
JCI Insight. 2024; 9(3).
PMID: 38329129
PMC: 10967472.
DOI: 10.1172/jci.insight.163359.
Pharmacology of LRRK2 with type I and II kinase inhibitors revealed by cryo-EM.
Zhu H, Hixson P, Ma W, Sun J
Cell Discov. 2024; 10(1):10.
PMID: 38263358
PMC: 10805800.
DOI: 10.1038/s41421-023-00639-8.
A potential patient stratification biomarker for Parkinson´s disease based on LRRK2 kinase-mediated centrosomal alterations in peripheral blood-derived cells.
Naaldijk Y, Fernandez B, Fasiczka R, Fdez E, Leghay C, Croitoru I
NPJ Parkinsons Dis. 2024; 10(1):12.
PMID: 38191886
PMC: 10774440.
DOI: 10.1038/s41531-023-00624-8.
PRKAA2, MTOR, and TFEB in the regulation of lysosomal damage response and autophagy.
Shariq M, Khan M, Raj R, Ahsan N, Kumar P
J Mol Med (Berl). 2024; 102(3):287-311.
PMID: 38183492
DOI: 10.1007/s00109-023-02411-7.
Human iPSC-derived microglia carrying the LRRK2-G2019S mutation show a Parkinson's disease related transcriptional profile and function.
Ohtonen S, Giudice L, Jantti H, Fazaludeen M, Shakirzyanova A, Gomez-Budia M
Sci Rep. 2023; 13(1):22118.
PMID: 38092815
PMC: 10719377.
DOI: 10.1038/s41598-023-49294-9.
Mitochondrial dysfunction in Parkinson's disease - a key disease hallmark with therapeutic potential.
Henrich M, Oertel W, Surmeier D, Geibl F
Mol Neurodegener. 2023; 18(1):83.
PMID: 37951933
PMC: 10640762.
DOI: 10.1186/s13024-023-00676-7.
Inhibition of the Exocyst Complex Attenuates the LRRK2 Pathological Effects.
Ciampelli C, Galleri G, Puggioni S, Fais M, Iannotta L, Galioto M
Int J Mol Sci. 2023; 24(16).
PMID: 37628835
PMC: 10454163.
DOI: 10.3390/ijms241612656.
Different pieces of the same puzzle: a multifaceted perspective on the complex biological basis of Parkinson's disease.
Muller-Nedebock A, Dekker M, Farrer M, Hattori N, Lim S, Mellick G
NPJ Parkinsons Dis. 2023; 9(1):110.
PMID: 37443150
PMC: 10345014.
DOI: 10.1038/s41531-023-00535-8.
Perspective on the current state of the LRRK2 field.
Taymans J, Fell M, Greenamyre T, Hirst W, Mamais A, Padmanabhan S
NPJ Parkinsons Dis. 2023; 9(1):104.
PMID: 37393318
PMC: 10314919.
DOI: 10.1038/s41531-023-00544-7.